Patients with a Ph-negative myeloproliferative neoplasm (MPN) may harbor or develop lymphoproliferative disorders (LPD), however, the clinical and molecular determinants of MPN and LPD co-occurrence are still uncertain. To systematically pool the available knowledge, we 
risk of developing LPD, to support surveillance programs and to avoid therapies possibly favoring LPD.
| I N TR ODU C TI ON
Patients with myeloproliferative neoplasms (MPN) experience a reduced survival and quality of life due to vascular events and transformation into acute leukemia. Besides, non-MPN cancers incur at a similar rate as vascular events 1 and contribute to limiting patients' their life span. 2 In particular, the cumulative incidence of lymphoproliferative disorders (LPD) in MPN patients has been reported to be significantly higher than the general population, 3 but only recently common cancerogenic pathways in MPN and LPD have started being unveiled. In particular, the JAK2 V617F mutation, which is harbored by a large portion of MPN patients, has been associated with an increased risk of lymphoma. 3, 4 Since available data are limited by small sample size, incomplete clinical details, and selection bias, we conducted a systematic scoping review of published literature to investigate the clinical characteristics of MPN patients incurring a LPD in the JAK2 era.
| M ET HOD S
We searched EMBASE, PubMed and Cochrane Library by the following queries:
1. (((("polycythemia vera") OR "thrombocythemia, essential") OR "myelofibrosis") OR "myeloproliferative disorders") AND ("leukemia, myeloid, acute" OR "leukemia, lymphocytic, chronic, B-cell"
OR "lymphoma" OR "neoplasms" OR "hematologic neoplasms"
[Mesh] NOR "myelodysplastic syndromes" NOR "leukemia, myeloid, acute") 2. (((("polycythemia vera") OR "thrombocythemia, essential") OR "myelofibrosis") OR "myeloproliferative disorders") AND ("cause of death" OR "mortality")
Retrieved records were subsequently filtered for publication date (from Figure S1 reports the reviewing process.
Chi-square test, Student's t-test and Wilcoxon-Mann-Whitney test were applied as appropriate.
| R E SU LTS

| General clinical characteristics
Clinical details of 214 patients were retrieved (Tables 1-4) : expected portions of patients reported a diagnosis of essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF), while unexpectedly most of the reported cases were males (ratio to female 1.56), even in the ET subgroup (male to female ratio equals 1.38).
One fifth of the patients reported a diagnosis of LPD preceding the diagnosis of MPN by a median of 42.5 months: the vast majority of them were males (83%; P 5 .047). Rather, half of the cases incurred LPD at a median of 72 months after the diagnosis of MPN (Table 3): this was the most frequent pattern in ET and younger patients (Tables   1 and 3 ). On converse, in patients with MF a concurrent diagnosis of LPD was more frequently reported (Table 1) .
| Lymphoproliferative disorders
Chronic lymphocytic leukemia (CLL) was the most common LPD, particularly among patients with LPD diagnosis preceding MPN (63% vs 46%; P 5 .066). CLL was reported in 59% of PV, 46% of MF, and 32%
of ET patients (P 5 .0014) and almost all the synchronous PV and LPD diagnoses included CLL ( Multiple myeloma was also frequently reported, however, this subgroup differed from the overall case series since both the male to female ratio (0.55 vs 1.74; P 5 .011) and the portion of JAK2-positive patients were significantly lower (52% vs 78%; P 5 .015) and because most of the diagnoses of MM were synchronous with that of MPN (53% vs 27%; P 5 .003). The occurrence of multiple myeloma was rare in PV patients (5% vs 21%; P 5 .004) and no case of MM diagnosis preceding MPN one was reported.
| Molecular issues
Out of 142 cases reporting molecular data, the JAK2 V617F mutation was present in vast majority, especially in those developing secondary LPD (75%). The portion of JAK2 mutated patients was especially high (83%) in those with a diagnosis of MF and a subsequent LPD diagnosis, however, these rates were not statistically significant. The clinical characteristics of JAK2-mutated individuals were somewhat different from unmutated ones: the former received MPN diagnosis at a significantly older age (69.5 versus 59 years, P 5 .001) and only 14% developed multiple myeloma (14% versus 26%; P 5 .015).
| Treatments and survival
Treatments employed for the MPN and LPD were reported in 47% and 43% of the retrieved cases, respectively, therefore the analyses were limited due to a small sample size (Table 4) . Based on the available data, MPN-targeted cytoreduction was provided to a similar rate to patients developing a secondary or a primary LPD.
Due to the paucity of information on patients' follow-up, we could estimate the survival from MPN diagnosis for 46 individuals ( 
| Molecular substrates of multiple primary cancers
Multiple primary cancers have been reported in LPD as well as in myeloproliferative disorders. 11, 12 Constitutional variants of oncogenes (i.e., p53, VHL) and SNPs have been associated with predisposition to multiple primary cancers. 13 In particular, the rs2736100_C single nucleotide polymorphism of the telomerase reverse transcriptase (TERT) gene is a strong susceptibility factor for MPN, lymphoid leukemias and solid cancers. 14-16 JAK2 V617F mutation itself, which is harbored by a large portion of MPN patients, increases the risk of developing blood cancers (HR 58) including lymphoma (HR 5.7) and solid cancers (HR 3.7). 3, 4 Moreover, the mutation has been reported in peripheral lymphocytes Notes: % are intended as percentage of column totals (adjusted for missing data). kinase target, after controlling myeloid proliferation with either ATRA or ruxolitinib. 18 Similarly, a 3-fold to more than 4-fold standardized risk of non-Hodgkin's lymphomas has been reported in patients with chronic myeloid leukemia or MPN receiving tyrosin kinase inhibitors.
12
Despite a positive prognostic role of lymphocytosis has been reported both in patients with chronic myeloid leukemia and myelofibrosis, 19, 20 no biologic explanation has been provided for such an observation, yet.
| Results of the systematic review
To ascertain the clinical and molecular determinants of concurrent LPD and MPN, we conducted a scoping review of published literature and identified 214 single patient records. The cohort showed a very high male-to-female ratio as compared with the two largest MPN cohort reported so far from the Swedish cancer registry and SEER being the ratio usually below 0.9, compared to 1.56 in the MPN cases developing LPD. 1, 21 Moreover, age at diagnosis was much higher than 70 years in population-based MPN cohorts, while it was 67 years in MPN cases who subsequently developed LPD in the case series we retrieved. Also, the portion of myelofibrosis patients was lower than 15%, while it was 23% in the LPD/MPN series. Indolent LPDs were the vast majority of the reported diagnoses, especially those preceding MPN diagnosis, however aggressive lymphomas were a relevant portion of LPDs occurring in the follow-up of MPN. A skewed occurrence of multiple myeloma preferentially in JAK2 unmutated and female patients was also evident in the retrieved cases. However, the high portion of synchronous diagnoses casts doubts on the possible misdiagnosis of MPN, rather than secondary fibrosis. Finally, an intriguing high rate of JAK2 V617F mutation was observed in MPN patients subsequently developing LPD, especially in those with MF.
| Limitations of the systematic review
The present review has several limitations besides the limited population size. In particular, publication bias might have limited the reporting of cases. Moreover, the high rate of missing data, especially survival and molecular data, and the largely heterogenous sources further limit the quality of the analyses. Furthermore, despite we selected recent publications, a portion of patients had received MPN and LPD diagnoses and treatments more than 20 years ago.
| Recent studies
Most recently, a nationwide case series of 83 Danish MPN patients concurrently or subsequently diagnosed LPD was presented: 32% presented aggressive lymphomas, 53% CLL or large granular lymphocyte leukemia and 10% peripheral T-cell lymphomas, especially angioimmunoblastic lymphoma. 22 Male-to-female ratio (1.08) and median age at MPN diagnosis (71 years) were similar to those reported by large MPN registries.
| Perspectives
Despite the number of reported patients with MPN and LPD is getting larger, still many clinical, molecular and outcome data are lacking and several clinical questions are still to be answered. Based on the systematic review we conducted, we deemed that matched controls could help verifying the associations we found between specific LPD and clinical-molecular features. Moreover, a longitudinal controlled study would be the only possible source for homogeneous outcome data. A multi-country retrospective case-control study is thus being started.
ORCID
Monia Marchetti
http://orcid.org/0000-0001-7615-0572
Tiziano Barbui http://orcid.org/0000-0003-2747-6327
